- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Epigenetic silencing of DSC3 is a common event in human breast cancer ; volume:7 ; number:5 ; day:16 ; month:6 ; year:2005 ; pages:1-12 ; date:10.2005
Breast cancer research ; 7, Heft 5 (16.6.2005), 1-12, 10.2005
- Urheber
-
Oshiro, Marc M.
- Beteiligte Personen und Organisationen
-
Kim, Christina J.
Wozniak, Ryan J.
Junk, Damian J.
Muñoz-Rodríguez, José L.
Burr, Jeanne A.
Fitzgerald, Matthew
Pawar, Sangita C.
Cress, Anne E.
Domann, Frederick E.
Futscher, Bernard W.
SpringerLink (Online service)
- DOI
-
10.1186/bcr1273
- URN
-
urn:nbn:de:1111-2016032356867
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oshiro, Marc M.
- Kim, Christina J.
- Wozniak, Ryan J.
- Junk, Damian J.
- Muñoz-Rodríguez, José L.
- Burr, Jeanne A.
- Fitzgerald, Matthew
- Pawar, Sangita C.
- Cress, Anne E.
- Domann, Frederick E.
- Futscher, Bernard W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Epigenetic silencing and deletion of the BRCA1gene in sporadic breast cancer
Epigenetic silencing of SALL 2 confers tamoxifen resistance in breast cancer
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
Genetic and epigenetic silencing of the beclin 1gene in sporadic breast tumors
Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Epigenetic silencing of serine protease HTRA1 drives polyploidy
Epigenetic silencing of MEIS2 in prostate cancer recurrence
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Pharmacologic reversion of epigenetic silencing of the PRKD1promoter blocks breast tumor cell invasion and metastasis
YAP represses intestinal inflammation through epigenetic silencing of JMJD3
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Epigenetic silencing and deletion of the BRCA1gene in sporadic breast cancer
Epigenetic silencing of SALL 2 confers tamoxifen resistance in breast cancer
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
Genetic and epigenetic silencing of the beclin 1gene in sporadic breast tumors
Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Epigenetic silencing of serine protease HTRA1 drives polyploidy
Epigenetic silencing of MEIS2 in prostate cancer recurrence
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Pharmacologic reversion of epigenetic silencing of the PRKD1promoter blocks breast tumor cell invasion and metastasis
YAP represses intestinal inflammation through epigenetic silencing of JMJD3
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Epigenetic silencing and deletion of the BRCA1gene in sporadic breast cancer
Epigenetic silencing of SALL 2 confers tamoxifen resistance in breast cancer
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
Genetic and epigenetic silencing of the beclin 1gene in sporadic breast tumors
Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Epigenetic silencing of serine protease HTRA1 drives polyploidy
Epigenetic silencing of MEIS2 in prostate cancer recurrence
Aberrant epigenetic and transcriptional events associated with breast cancer risk
Pharmacologic reversion of epigenetic silencing of the PRKD1promoter blocks breast tumor cell invasion and metastasis
YAP represses intestinal inflammation through epigenetic silencing of JMJD3